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Purine phosphoribosyltransferases (PRTs)1 of microbes and
mammals are enzymes that catalyze the recovery of preformed
bases for use in cellular metabolism. In free living organisms,
purine nucleotides can be generated via de novo synthesis, as well
as by the salvage of preformed bases. In contrast, many parasitic
organisms are unable to synthesize purines via de novo pathways
and therefore must rely on the enzymes in salvage pathways,
including PRTs, for the synthesis of purine nucleotides (1). For this
reason, enzymes in salvage pathways were proposed more than 30
years ago as potential targets of therapeutic agents for the treat-
ment of diseases caused by parasites (2).
Purine PRTs catalyze the reversible transfer of a phosphoribosyl
group from phosphoribosylpyrophosphate (PRPP) to a purine base
(adenine, guanine, hypoxanthine, or xanthine). For those enzymes
that have been studied, the forward reaction appears to be ordered
and sequential with PRPP binding first followed by the purine base
(3–5). After catalysis, pyrophosphate (PPi) is released before the
nucleotide. Reaction chemistry has been reported to proceed via
either a dissociative (Sn1) or an associative (Sn2) type mechanism
(Fig. 1). Based on their similarity to other enzymes, PRTs have
been proposed to catalyze an Sn1-type reaction with the formation
of an unstable ribooxocarbenium ion intermediate (6, 7), but Sn2-
type chemistry for purine PRTs has not been ruled out (8).
Enzymes in salvage pathways that contribute to the synthesis of
AMP include adenosine kinase or adenine phosphoribosyltrans-
ferase (APRT). Alternatively, adenosine deaminase and a purine
nucleoside phosphorylase catalyze the conversion of adenine to
hypoxanthine, which may be salvaged by hypoxanthine phospho-
ribosyltransferase (HPRT). The product, IMP, is a precursor for
both AMP and GMP. In most bacteria and nearly all eukaryotes,
HPRTs also catalyze the salvage of guanine and, in a few cases,
xanthine. In human tissues, substrates available for salvage in-
clude hypoxanthine at 8.2 6 1.3 mM, xanthine at 2.5 6 0.6 mM,
adenine at 0.3 6 0.15 mM, and adenosine at 0.6 6 0.2 mM (9). The
human HPRT can salvage xanthine, albeit at relatively low levels
(10), but instead this base is usually converted to uric acid for
excretion as a nitrogenous waste. The identity of the 6-oxopurine
substrates salvaged by HPRTs is frequently included in the names
of these enzymes, but HPRTs likely are descended from a common
ancestral hpt gene of prokaryotes, and substrate specificity can be
dramatically altered by single amino acid substitutions (11, 12).
Several bacteria possess two distinct enzymes for the salvage of
6-oxopurines. In those bacteria the primary substrate for the HPRT
is hypoxanthine, and guanine is utilized with reduced efficiency
(11). The other enzyme, referred to here as xanthine phosphoribo-
syltransferase (XPRT), has a preference for catalyzing the salvage
of guanine and xanthine.
The contributions of specific enzymes to the salvage of purine
bases vary significantly among different organisms. For example,
in Plasmodium falciparum, etiologic agent of the most lethal form
of human malaria, the activity of adenosine kinase is barely de-
tectable, and APRT activity is 1500-fold below that of HPRT (13).
In this pathogen, adenosine deaminase and purine nucleoside
phosphorylase are relatively abundant, suggesting that the major
route for the salvage of purine bases leading to both AMP and GMP
is through hypoxanthine, which can be converted to IMP by the
HPRT-catalyzed reaction.
Crystal Structures of Purine PRTs
For this review, residue numbers refer to the positions of amino
acids in the human HPRT, the bacterial XPRT, or the leishmanial
APRT, as these enzymes were the first of their class for which crystal
structures were reported (14–16). Fig. 2 illustrates ribbon diagrams
of monomers from these representative structures, although the en-
zymes may be functional as dimers or tetramers. All three of these
enzymes possess a core domain composed of a 4- or 5-stranded par-
allel b sheet flanked by 3–4 a helices. The C-terminal ends of the b
sheets of the core domains of purine PRTs form the floor of the active
sites of these enzymes. A poorly conserved hood domain contributes
residues that complete the active site and participate in binding
purine substrates. For HPRTs and XPRTs the amino acids that flank
the active site are contributed largely by 4 active site loops (loops
I–IV). Residues in the hood domains of HPRTs, XPRTs, and APRTs
come from non-homologous regions of the protein. However, all three
enzymes possess an aromatic residue that forms p-p stacking inter-
actions with purine substrates (Fig. 3).
Functional Roles for Conserved Amino Acids
Data reported to GenBankTM indicate that the HPRTs of distantly
related organisms share extensive primary sequence homology. For
example, there is 41% identity for amino acids in the human and a
bacterial HPRT (11). However, among well over 20 HPRT sequences
reported there are only 9 invariant amino acids and all but the HPRT
of Giardia lamblia also are invariant at Glu-133 and Asp-134 (Table
I). In general, conserved residues of HPRTs and bacterial XPRTs
differ at positions homologous with human Leu-67 and Glu-133
(Ser-36 and Asp-88 in the XPRT of Escherichia coli). Solutions for the
crystal structures of HPRTs reveal that the 11 conserved residues
immediately flank or are very near the active site of HPRTs (Fig. 3).
Among the amino acid sequences deduced from 39 APRT genes
reported to GenBankTM, 11 residues are invariant. As shown in
Fig. 3, these residues either flank the active site or are located
within active site loop II, which is predicted to participate in
forming the active site of APRTs during catalysis (16).
If the crystal structures of all purine PRTs are analyzed together
with the amino acid sequences reported to GenBankTM, there are
only 2 residues (corresponding with human Gly-69 and Asp-134)
that are clearly invariant. A G69E mutation virtually inactivates
the human HPRT, resulting in Lesch-Nyhan syndrome, whereas a
D134G mutation partially inactivates the enzyme, resulting in
gouty arthritis (17). The invariant glycine may be essential for the
formation of a tight turn and an unusual non-proline cis-peptide in
active site loop I of purine PRTs (15, 16, 18–23).
In nearly all purine PRTs, there is a lysine or arginine residue
located immediately upstream from the invariant glycine. There
have been several suggestions for the functional role of the cis-
peptide and the lysine (Lys-68) in active site loop I of HPRTs (20,
23, 24). The presence of the cis-peptide enables the carbonyl oxygen
and amide nitrogen, adjacent to the peptide bond, to interact with
pyrophosphate atoms and a metal-associated water molecule when
they are present in the active sites of HPRTs (21–23, 25). Closed
active site structures of HPRTs show that the side chain of Lys-68
forms multiple hydrogen bonds with residues in the opposing sub-
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unit in dimers of the enzyme (21, 22, 25). Changes in interactions
involving Lys-68, before and after closure of the active site, as the
enzyme approaches the transition state of the forward reaction
coincide with the weakening or breaking of hydrogen bonds be-
tween main chain atoms of loop I residues and ligands in the active
site (25). These interactions with active site ligands are replaced by
new hydrogen bonds with main chain atoms of residues in active
site loop II, which closes over the active site during the transition
state. These changes in hydrogen bond interactions with substrates
during closure of the active site may facilitate the liberation of
pyrophosphate from the active site after catalysis. Directed muta-
tion of Lys-68 to alanine in the human HPRT resulted in the
observation of positive cooperativity between subunits in the bind-
ing of PRPP, a result that is consistent with loop I being involved
in regulating binding interactions with PRPP and pyrophosphate
(24). Furthermore, in the HPRT of Tritrichomonas fetus (a proto-
zoan parasite of cattle), the threonine residue at position 68 was
proposed to affect the binding of PRPP and PPi to this enzyme (26).
All purine PRTs possess a dipeptide of acidic residues (human
HPRT position 133–134 or leishmanial APRT position 146–147)
within a conserved PRPP binding motif that spans 11 amino acids
and includes residues of active site loop III. Among purine PRTs,
the acidic dipeptide forms hydrogen bonds with the 29- and 39-
hydroxyls of ribose moieties of substrates (16, 18, 19, 21, 22, 25, 27).
Also, Glu-133 of HPRTs forms a hydrogen bond with a metal-
associated water molecule when it is present in the active site.
A Catalytic Base
Among HPRTs, the aspartate at position 137 was proposed to
play a role in catalysis by interacting with the N-7 position of
6-oxopurine substrates (21, 22, 28). Mutagenesis of the human
HPRT indicated that this aspartate likely functions as a catalytic
base by facilitating removal of a proton in forward reactions cata-
lyzed by HPRTs (28). Also, hydrogen bonding between this aspar-
tate and the purine N-7 position of a nucleotide analog may con-
tribute to the very tight binding of this inhibitor to HPRTs (21, 22).
The residue at the analogous location in the crystal structure of
the leishmanial APRT is a conserved alanine (Ala-150), suggesting
that either the catalytic mechanism differs between HPRTs and
APRTs or that the catalytic base of APRT is contributed by an
amino acid that moves to participate in the formation of the active
site during the transition state. In HPRTs, active site loop II has
been shown to close over the active site when both substrate li-
gands are bound and presumably during the transition state of the
reaction (21, 22, 25). Similarly, the x-ray crystal structure of the
leishmanial APRT with bound AMP hints that residues within
active site loop II of this enzyme may contribute to forming the
active site during the transition state (16). Thus, a catalytic base
might be contributed by a residue of active site loop II of APRTs.
A Site for Binding a Second Metal Ion
An aspartate at position 193 of HPRTs has been shown to par-
ticipate indirectly in binding pyrophosphate and purines via the
formation of a direct protein metal bond with a magnesium ion
(21–23, 25) designated M2 (Fig. 4). Asp-193 also forms hydrogen
bonds with two water molecules coordinated by the metal, and the
metal forms coordinated interactions with two oxygens of PRPP or
PPi. A third coordinated water molecule forms another hydrogen
bond with the N-3 atom of purine substrates. An invariant arginine
at position 199 of HPRTs participates directly in binding pyrophos-
phate (29) and may contribute to positioning both substrates by
being close enough to the carboxyl group of Asp-193 to affect its
position (21–23, 25). Together, these interactions help to position
both substrates for in-line nucleophilic attack at the C19 carbon of
PRPP or a nucleotide. A D193N mutation virtually inactivates the
human enzyme resulting in Lesch-Nyhan’s syndrome (17). An ex-
planation for the devastating effects of this mutation is revealed by
the existence of a hydrogen bond between the Asp-193 side chain
and the main chain nitrogen of Asp-196 together with a preference
of magnesium for interacting with oxygen over nitrogen. Thus, the
substitution of asparagine for aspartate at position 193 would
disfavor interactions with both Asp-196 and a magnesium ion.
FIG. 3. Conserved residues in the active sites of purine PRTs. The
enzyme from Trypanosoma cruzi is shown (numbered according to residues
in the human HPRT) in ternary complex with a purine analog and PRPP
(25). The bacterial XPRT is with guanine and a PRPP analog (19), and APRT
has bound AMP (16). The main chain atoms of invariant glycines and side
chains of other invariant amino acids are shown with thick bonds. Sub-
strates, substrate analogs, and conserved aromatic side chains that form p-p
stacking interactions with purine rings are illustrated with relatively thin
bonds.
TABLE I
The highly conserved residues of HPRTs, XPRTs, and APRTs
Residues that may have analogous functions in all purine PRTs are
printed in bold type. Although located at opposite ends of the protein se-
quences, Asp-193 of HPRTs, Asp-140 of bacterial XPRTs, and Asp-44 of
APRTs are located at analogous positions in enzyme crystal structures and
thus could possibly have similar functional roles (see text).














FIG. 1. Sn1 versus Sn2-type reaction mechanisms catalyzed by hy-
poxanthine PRTs. The ribooxocarbenium intermediate created in a two-
step Sn1 mechanism is compared with the predicted transition state for an
Sn2-type mechanism.
FIG. 2. Ribbon diagrams of the human HPRT (14), the XPRT of E.
coli (15), and the APRT of Leishmania donovani (16). The similar
orientations for the enzymes illustrate the conserved a/b structures of core
domains below the non-conserved structures of hood domains. Roman nu-
merals refer to active site loops I, II, and III.
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APRTs possess an invariant aspartate (Asp-44) that flanks the
putative PPi binding domain in the active site of the enzyme (Fig.
3). This suggests that a mechanism comparable with that of HPRTs
and XPRTs, for binding a second metal and positioning substrates,
could possibly exist for APRTs.
As of this writing, the only clear example in eucaryotes of multiple
enzymes for the salvage of 6-oxopurines is in Leishmania donovani
(30). In this protozoan parasite there is a gene encoding an “XPRT” as
well as an HPRT. The two enzymes appear to be the product of a
duplication of the hpt locus with both genes being expressed in extant
parasites. The leishmanial XPRT is novel in its preference for cata-
lyzing the salvage of xanthine over hypoxanthine and guanine. This
enzyme differs from all other 6-oxopurine PRTs in possessing gluta-
mate rather than aspartate at a position homologous with Asp-193 in
the human HPRT. This substitution would be predicted to affect the
positioning of the octahedrally coordinated second metal ion that
participates in positioning purine substrates in the active site. Pos-
sibly, the D193E substitution in the L. donovani XPRT is responsible
for the altered substrate specificity of this enzyme.
Roles for Residues in Active Site Loop II of HPRTs
As indicated in Table I, Ser-103 and Tyr-104 are invariant in
HPRTs and XPRTs. Both are located in loop II, which closes over
the active site during the transition state (Fig. 4). A S103R muta-
tion has been shown to impair the human HPRT, resulting in gouty
arthritis (17). The main chain carbonyl of Ser-103 forms a hydrogen
bond with a pyrophosphate oxygen atom of PRPP, whereas the side
chain hydroxyl interacts with a water molecule (Fig. 4, C). This
water forms an additional hydrogen bond with a conserved serine
(Ser-109), as well as to a 59-phosphate oxygen of either PRPP or a
nucleotide analog in the active site (21, 22, 25). These interactions
secure the base of the closed loop II and stabilizes its position over
the active site. Like the S103R mutation, a S109L mutation results
in partial inactivation of the human HPRT (17). Steady-state ki-
netic studies of these mutations in the human HPRT (31, 32),
together with contemporary structural data, indicate that loop II
also contributes to the stable binding of purine substrates. Possibly
this is achieved indirectly through van der Waals interactions of
loop II residues with conserved aromatic residues (homologous
with human Phe-186) that stack above purine substrates.
Analysis of the HPRT from L. donovani revealed that mutations
of the residue homologous with the tyrosine at position 104 of the
human HPRT severely reduce the turnover number (kcat) for the
forward reaction catalyzed by the enzyme (33). The main chain
nitrogen of Tyr-104 forms a hydrogen bond with a pyrophosphate
oxygen (Fig. 4), and the side chain hydroxyl forms a hydrogen bond
with a 59-phosphate oxygen atom of either PRPP or a nucleotide
analog in the active site (21, 22, 25). These interactions position the
aromatic ring of Tyr-104 directly above the location of the glycosidic
bond that would be formed or broken during catalysis and nearly
perpendicular to the ribose ring. Thus, the aromatic ring of tyrosine
helps to isolate the reaction center from bulk solvent and could
possibly provide partial electrostatic stabilization for a positively
charged intermediate in an Sn1-type reaction.
Specificity for 6-Oxo- and 6-Aminopurine Substrates
An invariant lysine residue at position 165 in the human HPRT
forms a hydrogen bond with the exocyclic oxygen of 6-oxopurine
bases (14). The homologous residue in the HPRT of T. fetus has
been demonstrated by site-directed mutagenesis to be the determi-
nant for 6-oxopurine substrate specificity (12). In the only available
structure for an APRT, specificity for 6-aminopurines appears to be
determined by the formation of a hydrogen bond with a main chain
carbonyl atom of an arginine residue at position 41 (16).
The Catalytic Mechanism of HPRTs
The discovery of two metal ions in the active sites of HPRTs has
important implications for the chemistry of the reaction catalyzed
by this enzyme. The electron withdrawing potential of the metal
ions may contribute to activation of PPi as a leaving group in
HPRT-catalyzed reactions. The metal designated M1 forms no di-
rect interactions with active site residues (Fig. 4). However, 4
oxygen atoms belonging to either PRPP or PPi and the ribose
moiety of nucleotide substrates (atoms designated O-1, O-29, O-39,
O-3B) are within the coordination sphere of this metal (21, 22, 25).
In the structure of the trypanosomal HPRT, with PRPP and a
purine analog as ligands, the length of the coordinated interaction
of M1 with the O-1 atom of PRPP is too long (at 2.6 Å) to satisfy
optimally the metal coordination sphere (25). Thus, the electron-
withdrawing potential of M1, along with formation of the sixth
metal bond to O-1 as the reaction approaches the transition state,
may contribute to lowering the activation energy for catalysis.
Previous kinetic studies (6, 7) suggest that HPRTs catalyze an
Sn1-type chemical reaction (Fig. 1) where an unstable ribooxocar-
benium intermediate would need to be protected from bulk solvent.
The deletion of 7 residues from active site loop II of the trypano-
somal HPRT does not prevent the enzyme from catalyzing either
forward or reverse reactions, albeit at extremely reduced catalytic
efficiencies (34). This indicates that total isolation from bulk sol-
vent is not required for the protection of a highly unstable inter-
mediate in the reaction. Furthermore, x-ray crystal structures of
the closed active sites of the human, malarial, and trypanosomal
HPRTs reveal that the only residue near enough to provide stabi-
lization of a positively charged intermediate is an invariant tyro-
sine (human Tyr-104), which is located above the ribose ring of
bound substrates (21, 22, 25). This suggests that these enzymes
could provide only minimal electrostatic stabilization for a ribooxo-
carbenium intermediate formed during an Sn1-type reaction.
An obvious question that arises from the structure of trypano-
somal and human HPRTs with PRPP bound (24, 25) is why wasn’t
the PRPP cleaved. In these structures, PRPP is present in the
closed active sites and the metal (M1) is poised to move closer to the
O-1 atom to assist further in pulling electrons away from the
covalent bond that is to be broken. If Sn1 chemistry were involved,
the first half of the reaction might be expected to occur, resulting in
dissolution of the covalent bond between PPi and the ribose mono-
phosphate. However, the reaction seems to be awaiting nucleo-
philic attack by the purine base, which cannot occur in the reported
structures because of the non-reactive purine analog in the active
site. Thus, these crystal structures provide evidence for the reac-
tion being associative (Sn2) rather than dissociative (Sn1).
The Design or Discovery of HPRT Inhibitors
Prior to 1999, few HPRT inhibitors had been identified and most
yielded Ki values above 10 mM. An exception was a nucleotide
analog, carbocyclic GMP, with an IC50 of 0.87 mM versus a mam-
malian HPRT (35). Recent progress in enzyme structure-based
inhibitor design/discovery shows promise that HPRT inhibitors
FIG. 4. A cross-eyed stereo view of the
closed active site of the HPRT from
Trypanosoma cruzi in ternary complex
with substrate ligands (25). Interactions
between active site ligands and amino acids
in loop II are shown. Active site loops I, III,
and IV are diagrammed as ribbons, and all
non-hydrogen atoms of the closed loop II are
illustrated. Water “C” is hydrogen bonded to
the 59-phosphate of PRPP as well as to the
side chains of both Ser-103 (not labeled) and
Ser-109 (see text). HPP, hydroxypyrazolopy-
rimidine. This figure has been reprinted
with permission from Biochemistry (25). To
view three-dimensionally, cross eyes slightly
and focus on the central thrid image.
Minireview: Purine Phosphoribosyltransferases 20233
eventually might be developed into drugs for the treatment of
diseases caused by parasites. In this regard, the de novo design of
mechanistic inhibitors, including transition state analogs and mul-
tisubstrate inhibitors, provides an approach to the discovery of
potent inhibitors of HPRT activity (36).
Success in the de novo design of a mechanistic type of inhibitor
was achieved recently in a series of non-hydrolyzable nucleotide
analogs (immucillin 59-phosphates). As inhibitors of reverse reac-
tions catalyzed by the human HPRT, these compounds yield Ki
values in the range of 56–250 nM (37). However, because of “slow
onset inhibition,” secondary Ki values, determined from the rates of
product formation after 2 h in the presence of substrates and
inhibitor, were between 1.0 and 14 nM. Although structurally sim-
ilar to carbocyclic GMP (35), the immucillins differ in that they
mimic chemical requirements predicted to exist in the transition
state of HPRT-catalyzed reactions (37). Specifically, the immucil-
lins possess nitrogen instead of oxygen in the ring of the ribose
moiety and a proton at the N-7 position of the purine moiety. The
N-7 proton (predicted to exist for both Sn1- and Sn2-type reaction
mechanisms) enables the formation of a hydrogen bond with the
invariant Asp-137 residue of HPRTs (21, 22). The nitrogen atom in
the ribose ring allows for the formation of a positive charge on the
analog of the ribose moiety at physiological pH. In theory, the
charge mimics the electrostatic surface potential predicted for a
ribooxocarbenium intermediate in Sn1-type reactions. Crystal
structures of the human and malarial HPRTs were solved with
immucillin inhibitors bound (21, 22). Surprisingly, these structures
reveal no strong electrostatic interactions between enzyme resi-
dues and the electropositive ribose ring. In explanation, the au-
thors suggest that transition state stabilization is achieved by
intramolecular interactions involving the 59-phosphate of the sub-
strate analog (21). Also, some stabilization could be provided by
interactions with the magnesium-coordinated pyrophosphate sub-
strate, whose presence was required to achieve the low Ki values for
“slow onset” inhibition (37). Thus, the 2.8-Å hydrogen bond be-
tween the N-7 proton of the purine moiety and the invariant as-
partate at position 137 (21, 22) as well as altered conformation of
the plane of the ribose ring may account for the tight binding
characteristics of the inhibitors.
Unfortunately, immucillin 59-phosphates cannot be tested in
their present form as inhibitors of the growth of parasites in vivo
because they would have difficulty crossing plasma membranes to
get to the target enzyme. Also, an intrinsic potential disadvantage
of mechanism-based inhibitors is that that they may target all
PRTs that have a similar enzyme mechanism, and it may be more
difficult to achieve selectivity for binding to the enzymes of patho-
gens. Thus, a combined approach of mechanism- and structure-
based design may be required to achieve target selectivity in mech-
anism-based inhibitors.
Computational efforts to identify HPRT inhibitors using the
x-ray crystal structures of target enzymes have been reported. For
example, the rigid body program “DOCK” was used to identify a
240 mM inhibitor of the HPRT from T. fetus (38). Derivatives of this
lead inhibitor were shown to yield Ki values of 12 mM (38) and 49 nM
(39) versus the HPRT from T. fetus. IC50 value determinations with
human and tritrichomonal HPRTs indicate that the compounds
selectively inhibited the enzyme of the parasite. Inhibition of the
growth of parasites in vitro by these compounds was reversed by
the addition of excess purines in the medium, providing evidence
that the HPRT was the most likely target of the inhibitor (38, 39).
These are the first reports in which an HPRT inhibitor has been
shown to be effective in slowing the growth of a protozoan parasite.
Concluding Remarks
Purine PRTs have been studied extensively during the latter
half of the twentieth century. A number of crystal structures have
been solved, and considerable data are available from studies of
amino acid substitutions that provide insights into structure/func-
tion relationships for this important class of metabolic enzymes.
Mechanistic studies and enzyme structures have been used in the
design and analysis of inhibitors of HPRTs, showing promise that
the chemical knock-out of HPRT activity may be achieved within
the next few years. Such inhibitors would represent novel leads for
the development of drugs for the treatment of diseases caused by
protozoan parasites.
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